FDA Designates MDMA As ‘Breakthrough Therapy’ For Post-Traumatic Stress

Following years of lobbying and laboratory research on the medical uses of methylenedioxymethamphetamine, or MDMA, the U.S. Food and Drug Administration has decided to move forward with the drug.

Last week, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the FDA has granted Breakthrough Therapy Designation to MDMA for the treatment of post-traumatic stress disorder (PTSD). Popularly known as a recreational drug, and as the main ingredient in ecstasy, MDMA has been shown to offer significant relief for sufferers of PTSD in clinical use trials conducted over the past several years, leading to the U.S. agency’s decision.

MAPS, which has been championing and fundraising for MDMA research for roughly 30 years, explained in a press release that the FDA’s granting of a Breakthrough Therapy Designation indicates the agency “has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD.” It also designates the agency’s intent to help develop and reviewthe treatment faster than other candidate therapies.

Read the full Forbes article.

Source link